Microbix Q3 FY26 net loss narrows to $806,762; revenue rises 17% to $4.06 million

• Microbix posted Q3 fiscal 2026 revenue of $4.06 million, up 17% year over year.
• Net loss narrowed to $806,762 from $1.64 million; gross margin rose 13 percentage points to 54%.
• Nine-month revenue fell 21% to $11.66 million, on a more than $4 million drop in antigen sales to a China distributor.
• Nine-month net loss widened to $3.4 million from $765,150; cash used in operations increased to $3.38 million.
• Management flagged readiness for material sales growth, targeting new clients after 2025 setbacks; expects full-year results in line with its MD&A outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbix Biosystems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608130750ACCESSWRNAPR_____1206908) on August 13, 2026, and is solely responsible for the information contained therein.